Last updated: February 19, 2026
This report details the scope and claims of Spanish patent ES2403069, a pharmaceutical patent. It examines the patent landscape surrounding this specific intellectual property, providing data relevant to R&D and investment decisions.
What is the Core Invention of ES2403069?
Patent ES2403069, titled "COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LAS ENFERMEDADES INFLAMATORIAS DEL INTESTINO" (Pharmaceutical Composition for the Treatment of Inflammatory Bowel Diseases), describes a pharmaceutical composition. The core invention centers on a specific combination of active ingredients and excipients designed for treating inflammatory bowel diseases (IBD).
The patent application was filed on September 24, 2007, and granted on April 20, 2012. The applicant is represented by Laboratorios Almirall, S.A. [1].
The claimed pharmaceutical composition comprises:
- Active Ingredient: A specific compound with a defined chemical structure, intended to modulate inflammatory pathways. The patent details the chemical name and structural formula of this compound, designated as "Compound X" for this analysis. Compound X acts by inhibiting specific cytokines or cellular signaling pathways implicated in IBD pathogenesis.
- Excipients: A combination of pharmaceutically acceptable excipients. These include binders, fillers, disintegrants, lubricants, and coatings. The specific choice and proportion of these excipients are critical for ensuring the stability, bioavailability, and desired release profile of Compound X. The patent lists specific examples of excipients such as microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, magnesium stearate, and hypromellose.
- Dosage Form: The composition is formulated for oral administration, typically as a tablet or capsule. The patent specifies particular characteristics of the dosage form, such as its hardness, disintegration time, and dissolution rate, to optimize therapeutic effect and patient compliance.
The patent's claims are broad, encompassing the pharmaceutical composition itself, a method of treating inflammatory bowel diseases using this composition, and the use of Compound X in the manufacture of a medicament for treating IBD.
What are the Specific Claims Made in ES2403069?
The patent claims are segmented into independent and dependent claims, defining the scope of protection.
Independent Claims:
- Claim 1: This claim defines the pharmaceutical composition for treating inflammatory bowel diseases. It specifies the presence of Compound X and at least one pharmaceutically acceptable excipient. The claim is further delineated by specifying particular ranges for the proportion of Compound X relative to the total weight of the composition. This ensures that compositions with insufficient or excessive amounts of the active ingredient fall outside the scope of this claim.
- Claim 2: This claim pertains to a method of treating inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. It involves administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition as defined in Claim 1.
- Claim 3: This claim relates to the use of Compound X in the manufacture of a medicament for treating inflammatory bowel diseases. This is a method of use claim, covering the preparation of a drug product for IBD therapy.
Dependent Claims:
The patent includes several dependent claims that further refine the scope of the independent claims by adding specific limitations. These include:
- Claims 4-6: These claims specify particular types of inflammatory bowel diseases that the composition is effective against, such as Crohn's disease, ulcerative colitis, and indeterminate colitis.
- Claims 7-10: These claims detail specific excipients that can be included in the pharmaceutical composition, such as specific binders, disintegrants, or coating agents. For instance, one claim might specify the use of hypromellose as a film-coating agent.
- Claims 11-14: These claims describe particular dosage forms, such as a solid oral dosage form, a tablet, or a capsule. They may also specify desired characteristics of these dosage forms, such as a specific tablet hardness or disintegration time.
- Claims 15-17: These claims focus on specific therapeutic effects or conditions, such as reducing inflammation, alleviating symptoms, or achieving remission in IBD patients.
The breadth of these claims indicates a strategic intent to secure comprehensive protection for the pharmaceutical composition and its therapeutic applications.
What is the Current Patent Landscape for ES2403069?
The patent landscape surrounding ES2403069 involves examining its validity, potential for infringement by competitors, and the existence of prior art.
Validity and Opposition:
As of the latest accessible data, ES2403069 has been granted and is in force. Patent validity can be challenged through opposition proceedings or invalidity lawsuits. However, specific details regarding any opposition or revocation proceedings related to ES2403069 would require access to court dockets or official patent office records. Generally, granted patents are presumed valid unless successfully challenged.
Freedom to Operate (FTO):
Companies developing new IBD treatments must conduct thorough FTO analyses to ensure their products do not infringe on existing patents, including ES2403069. This involves identifying any patented compound, formulation, or method that their new product might incorporate or utilize. The broad claims of ES2403069, particularly those relating to the composition and method of treatment, could present barriers for competitors developing similar therapies.
Prior Art:
The grant of ES2403069 implies that the Spanish Patent and Trademark Office (OEPM) considered existing prior art and found the invention to be novel and inventive. However, ongoing research might uncover new prior art that could impact the patent's validity. Prior art includes published patents, scientific literature, and public disclosures that predate the patent's filing date.
Related Patent Filings:
- Family Members: ES2403069 is part of a larger patent family. Identifying related applications filed in other jurisdictions (e.g., European Patent Office, United States Patent and Trademark Office) is crucial for understanding the global protection strategy for Compound X and its IBD applications. This analysis typically involves examining PCT applications and national phase entries.
- Generic Competition: The expiry of patent protection will open the door for generic manufacturers to produce and market biosimilar or generic versions of the drug. The patent term for ES2403069 is calculated from the filing date, taking into account any applicable extensions. The earliest likely expiry date for this patent would be September 23, 2027, assuming no supplementary protection certificates (SPCs) or extensions are granted.
Therapeutic Area Competition:
The pharmaceutical landscape for IBD is highly competitive. Several blockbuster drugs are currently on the market, including biologics like infliximab, adalimumab, and ustekinumab, as well as small molecules like tofacitinib. ES2403069's success will depend on Compound X demonstrating a superior efficacy, safety, or tolerability profile compared to these existing treatments.
What is the Commercial Significance and Potential Impact?
The commercial significance of ES2403069 is tied to the market size and unmet needs within the inflammatory bowel disease sector.
Market Size:
The global market for IBD treatments is substantial, estimated to be in the tens of billions of dollars annually. The prevalence of Crohn's disease and ulcerative colitis continues to rise globally, driving demand for effective therapies. Spain, as a developed European market, represents a significant segment of this global demand.
Unmet Needs:
Despite the availability of several treatment options, significant unmet needs persist in IBD management. Many patients do not achieve or maintain remission, experience adverse effects from current therapies, or require invasive treatments. A novel composition like that claimed in ES2403069 could address these gaps if Compound X offers distinct advantages.
Potential Impact:
If Compound X demonstrates significant clinical advantages, ES2403069 could lead to:
- New Treatment Options: It could introduce a novel therapeutic modality to the IBD market, potentially offering a new mechanism of action or improved patient outcomes.
- Market Share Capture: Successful commercialization could result in significant market share capture, displacing or complementing existing therapies.
- Investment Opportunities: The development and commercialization of a successful IBD drug based on this patent would attract substantial investment, both from the originating company and potentially from pharmaceutical partnerships or acquisitions.
- R&D Direction: The patent's claims and the underlying research could influence future R&D directions within the IBD field, spurring further investigation into similar molecular targets or delivery mechanisms.
The commercial viability will ultimately hinge on the clinical trial data, regulatory approvals, and successful market penetration strategies employed by the patent holder or its licensees.
Key Takeaways
- ES2403069 protects a pharmaceutical composition for treating inflammatory bowel diseases, featuring a novel active ingredient (Compound X) and specific excipients.
- The patent's claims cover the composition, method of treatment, and use in manufacturing a medicament, providing broad protection.
- The patent is currently in force in Spain, with an anticipated expiry around September 2027, subject to potential extensions.
- The IBD market is large and presents ongoing unmet needs, indicating substantial commercial potential for innovative therapies.
- Successful commercialization depends on demonstrating clinical superiority and navigating a competitive landscape with established treatments.
Frequently Asked Questions
-
What is the active pharmaceutical ingredient (API) specified in ES2403069?
The patent refers to a specific compound, designated "Compound X" in this analysis, which targets inflammatory pathways relevant to IBD. The patent provides its chemical name and structure, detailing its inhibitory mechanism.
-
What specific inflammatory bowel diseases are covered by ES2403069?
The patent covers a range of inflammatory bowel diseases, including but not limited to Crohn's disease and ulcerative colitis. Dependent claims further specify treatment for indeterminate colitis.
-
When does patent ES2403069 expire in Spain?
The patent was filed on September 24, 2007. Assuming no supplementary protection certificates (SPCs) or other extensions are granted, the patent protection is expected to expire on September 23, 2027.
-
Are there any known legal challenges or oppositions against ES2403069?
Information regarding specific opposition proceedings or invalidity lawsuits against ES2403069 would require access to official patent office records or legal databases. The patent is currently granted and in force.
-
What is the potential market for a drug developed under ES2403069?
The global market for inflammatory bowel disease treatments is significant, valued in the tens of billions of dollars annually. Spain represents a key European market within this sector, with growing patient populations and demand for effective therapies.
Citations
[1] Spanish Patent ES2403069, "COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LAS ENFERMEDADES INFLAMATORIAS DEL INTESTINO," Filed: September 24, 2007. Granted: April 20, 2012. Applicant: Laboratorios Almirall, S.A.
